Teva Pharmaceutical Industries

Teva presented positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult schizophrenia patients at ECNP 2024. The three doses align with oral olanzapine doses, simplifying physician transitions, and no new safety signals or PDSS were observed.

Teva Pharmaceuticals announces positive results for Phase 3 SOLARIS trial evaluating TEV-‘749 in schizophrenia patients, showing significant improvements in PANSS, CGI-S, and PSP scores with no incidence of PDSS.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

DEA allows increased production of Vyvanse to address ADHD and BED treatment shortages, with 25% for domestic and 75% for foreign demand. Despite FDA approval for generic Vyvanse production, shortages persist due to active ingredient issues. DEA's quota-setting process faces criticism for causing shortages, prompting consideration of more transparent methods. Vyvanse remains the most popular stimulant among ADDitude survey respondents.

The Judicial Court of Paris revoked Sanofi’s EP 2 493 466 patent on cabazitaxel due to obviousness, marking another setback in the dispute with generic drug companies over Jevtana. French judges consistently favor generics in pharmaceutical disputes. Sanofi’s second medical use patent for cabazitaxel, used in Jevtana, faces ongoing challenges from Teva, Accord Healthcare, and Ever Pharma. The EPO Technical Boards of Appeal will hear an appeal against the patent’s grant in April 2025, and UPC cases are pending.

The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.

The U.S. DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% due to ongoing ADHD drug shortages, with 13,478 pounds allocated for domestic and foreign demand.

Novo Nordisk launches Wegovy® in Australia for weight loss. Xbrane regains certolizumab biosimilar rights. BMS’ Opdivo® gains new NSCLC indication in Australia. Teva’s Q2 revenue grows 7%. Celltrion’s ustekinumab biosimilar approved in Canada. Zydus’ trastuzumab biosimilar approved in Mexico. PBAC agenda includes denosumab & ustekinumab biosimilars. UPC hears omalizumab patent dispute. Biogen’s Leqembi® shows Alzheimer’s benefits. Samsung Bioepis revokes Janssen’s Stelara® patent in UK. Bio-Thera/Sandoz’s bevacizumab biosimilar approved in EU. Roche’s Vabysmo® approved for RVO in EU. FDA approves J&J’s Darzalex Faspro® for multiple myeloma. Formycon’s pembrolizumab biosimilar enters Phase III. US indicts for counterfeit cancer drugs. Roche’s Vabysmo® approved for RVO in Canada. NICE against trastuzumab deruxtecan for HER2-low breast cancer. Amgen’s Xgeva® PFS approved in Korea. FDA alerts on compounded semaglutide imitations. Regeneron disclaims aflibercept patent after adverse IPR decision.